MK-0941

CAS : 1137916-97-2

Ref. 3D-MVB91697

Informations sur le produit

• Nom: MK-0941
• CAS: 1137916-97-2

Description

MK-0941 is a potential therapeutic for the treatment of type 2 diabetes. It is a novel, orally active, small molecule that has been shown to reduce blood glucose levels in preclinical models. MK-0941 targets pancreatic and hepatic steatosis by inhibiting the uptake of triglycerides from plasma into these tissues. MK-0941 also increases insulin sensitivity in vitro and in vivo. This drug has been studied as monotherapy at doses of 0.1, 1, or 10 mg/kg and as combination therapy with metformin at doses of 5 or 25 mg/kg in db/db mice and wild-type mice. The study drug was well tolerated up to 10 mg/kg without any adverse effects on body weight or food intake observed.
MK-0941 has shown promising results in lowering blood glucose levels and improving insulin sensitivity when administered alone or in combination with metformin at high doses.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 556.61 g/mol
• Formule: C₂₂H₂₈N₄O₉S₂
• Degré de pureté: Min. 95%